Oragenics Inc (OGEN) - Net Assets
Based on the latest financial reports, Oragenics Inc (OGEN) has net assets worth $6.18 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.49 Million) and total liabilities ($1.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Oragenics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.18 Million |
| % of Total Assets | 82.54% |
| Annual Growth Rate | 4.07% |
| 5-Year Change | -68.73% |
| 10-Year Change | 179.24% |
| Growth Volatility | 89.65 |
Oragenics Inc - Net Assets Trend (2003–2025)
This chart illustrates how Oragenics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Oragenics Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Oragenics Inc (2003–2025)
The table below shows the annual net assets of Oragenics Inc from 2003 to 2025. For live valuation and market cap data, see OGEN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.28 Million | +4008.44% |
| 2024-12-31 | $-211.88K | -106.69% |
| 2023-12-31 | $3.17 Million | -75.65% |
| 2022-12-31 | $13.01 Million | -50.88% |
| 2021-12-31 | $26.49 Million | +57.24% |
| 2020-12-31 | $16.84 Million | -2.25% |
| 2019-12-31 | $17.23 Million | -17.48% |
| 2018-12-31 | $20.88 Million | +230.60% |
| 2017-12-31 | $6.32 Million | +112.98% |
| 2016-12-31 | $2.97 Million | -37.31% |
| 2015-12-31 | $4.73 Million | -54.23% |
| 2014-12-31 | $10.34 Million | -34.74% |
| 2013-12-31 | $15.84 Million | +71.57% |
| 2012-12-31 | $9.23 Million | +212.87% |
| 2011-12-31 | $-8.18 Million | -330.65% |
| 2010-12-31 | $-1.90 Million | -171.95% |
| 2009-12-31 | $2.64 Million | +1589.23% |
| 2008-12-31 | $-177.25K | -121.62% |
| 2007-12-31 | $819.88K | -35.86% |
| 2006-12-31 | $1.28 Million | -27.85% |
| 2005-12-31 | $1.77 Million | -56.11% |
| 2004-12-31 | $4.04 Million | +17.34% |
| 2003-12-31 | $3.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oragenics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22423456300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.27K | 0.05% |
| Other Components | $234.91 Million | 2836.55% |
| Total Equity | $8.28 Million | 100.00% |
Oragenics Inc Competitors by Market Cap
The table below lists competitors of Oragenics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jost AG
MU:JOX
|
$2.42 Million |
|
Millennium Food-Tech LP
TA:MIFT
|
$2.42 Million |
|
Fuller Smith & Turner
LSE:FSTA
|
$2.42 Million |
|
Winchester Energy Ltd
AU:WEL
|
$2.42 Million |
|
Global Battery Metals Ltd
V:GBML
|
$2.42 Million |
|
Performance One AG
F:PO1
|
$2.41 Million |
|
Multipolar Tbk
JK:MLPL
|
$2.41 Million |
|
Northern Lion Gold Corp
V:NL
|
$2.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oragenics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -211,885 to 8,281,405, a change of 8,493,290.
- Net loss of 9,842,487 reduced equity.
- New share issuances of 17,653,890 increased equity.
- Other factors increased equity by 681,887.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.84 Million | -118.85% |
| Share Issuances | $17.65 Million | +213.18% |
| Other Changes | $681.89K | +8.23% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Oragenics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.15x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $3104.60 | $0.58 | x |
| 2004-12-31 | $3455.86 | $0.58 | x |
| 2005-12-31 | $1410.49 | $0.58 | x |
| 2006-12-31 | $765.89 | $0.58 | x |
| 2007-12-31 | $392.10 | $0.58 | x |
| 2008-12-31 | $-60.66 | $0.58 | x |
| 2009-12-31 | $488.28 | $0.58 | x |
| 2010-12-31 | $-206.78 | $0.58 | x |
| 2011-12-31 | $-858.36 | $0.58 | x |
| 2012-12-31 | $312.31 | $0.58 | x |
| 2013-12-31 | $330.21 | $0.58 | x |
| 2014-12-31 | $171.54 | $0.58 | x |
| 2015-12-31 | $77.44 | $0.58 | x |
| 2016-12-31 | $39.89 | $0.58 | x |
| 2017-12-31 | $76.93 | $0.58 | x |
| 2018-12-31 | $96.09 | $0.58 | x |
| 2019-12-31 | $24.45 | $0.58 | x |
| 2020-12-31 | $17.88 | $0.58 | x |
| 2021-12-31 | $14.07 | $0.58 | x |
| 2022-12-31 | $6.48 | $0.58 | x |
| 2023-12-31 | $1.41 | $0.58 | x |
| 2024-12-31 | $-0.03 | $0.58 | x |
| 2025-12-31 | $3.84 | $0.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oragenics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -118.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-118.85%) is above the historical average (-137.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -48.63% | 0.00% | 0.00x | 1.06x | $-2.02 Million |
| 2004 | -76.25% | -1568.67% | 0.04x | 1.11x | $-3.48 Million |
| 2005 | -183.51% | 0.00% | 0.00x | 1.21x | $-3.43 Million |
| 2006 | -229.66% | -4436.23% | 0.04x | 1.26x | $-3.06 Million |
| 2007 | -281.99% | -1737.20% | 0.12x | 1.40x | $-2.39 Million |
| 2008 | 0.00% | -2578.58% | 0.15x | 0.00x | $-6.00 Million |
| 2009 | -209.08% | -860.62% | 0.20x | 1.21x | $-5.78 Million |
| 2010 | 0.00% | -596.26% | 0.76x | 0.00x | $-7.62 Million |
| 2011 | 0.00% | -531.79% | 1.14x | 0.00x | $-6.86 Million |
| 2012 | -141.79% | -982.73% | 0.13x | 1.14x | $-14.01 Million |
| 2013 | -101.45% | -1557.07% | 0.06x | 1.06x | $-17.65 Million |
| 2014 | -56.01% | -615.95% | 0.08x | 1.08x | $-6.82 Million |
| 2015 | -247.54% | -995.83% | 0.20x | 1.22x | $-12.18 Million |
| 2016 | -236.48% | 0.00% | 0.00x | 1.45x | $-7.31 Million |
| 2017 | -106.57% | 0.00% | 0.00x | 1.14x | $-7.36 Million |
| 2018 | -47.48% | 0.00% | 0.00x | 1.06x | $-12.00 Million |
| 2019 | -90.38% | 0.00% | 0.00x | 1.15x | $-17.30 Million |
| 2020 | -156.91% | 0.00% | 0.00x | 1.11x | $-28.12 Million |
| 2021 | -59.32% | -18062.03% | 0.00x | 1.07x | $-18.36 Million |
| 2022 | -109.83% | -10863.96% | 0.01x | 1.13x | $-15.59 Million |
| 2023 | -651.98% | -54858.14% | 0.01x | 1.57x | $-20.97 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.55 Million |
| 2025 | -118.85% | 0.00% | 0.00x | 1.22x | $-10.67 Million |
Industry Comparison
This section compares Oragenics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $75,073,976
- Average return on equity (ROE) among peers: -30.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oragenics Inc (OGEN) | $6.18 Million | -48.63% | 0.21x | $2.42 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $93.41 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.40 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $302.62 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $169.73 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $771.73 Million |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $9.51 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $309.49 Million | -29.88% | 0.05x | $3.59 Billion |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more